Business Wire

 QCT, Radisys and Intel Deliver vRAN Solution for 5G

29.6.2021 19:00:00 EEST | Business Wire | Press release

Share

Quanta Cloud Technology (QCT), a global data center solution provider, announced OmniRAN, its virtualized radio access network (vRAN) solution developed with its long-term partners, Intel and Radisys. The solution uses Intel FlexRAN , a cloud-enabled wireless access virtual network functions reference implementation, and Radisys Connect 5G RAN software, a disaggregated RAN architecture for promoting 4G, 5G and IoT to build a cloud-native vRAN based on 3rd Gen Intel Xeon Scalable Processors running on QCT EGX63IS-1U servers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005459/en/

To deliver low-latency and power-efficient services with the flexibility to increase or decrease capacity based on the volume of real-time traffic demands, Intel’s vRAN dedicated accelerator, ACC100, for forward error correction (FEC) acceleration is also an essential part of the integrated solution. Intel’s 5G optimized network adapter, codenamed Westport Channel, is also implemented for accurate time synchronization without the added complexity or expenses that come with specialty timing hardware. This validated combination on QCT EGX63IS-1U extends distributed unit (DU) capabilities to support multi-cell and multi-RRU 5G scenarios, delivering reliable performance for various network workloads.

As operators are increasingly looking for ways to accelerate their 5G network deployments by leveraging disaggregated and open reference architecture solutions, OpenRAN-based OmniRAN is designed to minimize the challenges of infrastructure deployment and maximize value of ownership. OmniRAN has already been successfully deployed in smart manufacturing use cases such as safety AI for environment control, high-resolution streaming for quality control, AR goggles for maintenance and repair, and autonomous guided vehicles (AGV) for equipment transport. Not only does OmniRAN provide improved performance such as wider coverage and enhanced mobility, but also offer centralized management as well as greater scalability and deployment flexibility while achieving significant cost savings.

“QCT works closely with its partners to ensure that customers can always stay ahead of the game,” said Mike Yang, President of QCT. “Incorporating the newest technologies and features from Intel and Radisys, QCT’s latest vRAN solution improves capital and operational efficiencies by optimizing resource utilization and making software-defined management and orchestration possible.”

“Open 5G networks are the next step for customers across many sectors, and Radisys, along with our partners, is providing open, disaggregated and virtualized RAN solutions to meet varying business demands,” said Munish Chhabra, head of Mobility Software and Services Business, Radisys. “We are excited to power the QCT vRAN solution through our market first Release 16 Radisys 5G software stack. The integrated solution enables mobile operators and enterprises to benefit from reduced costs, improved network efficiencies, and faster time-to-market of new services that open APIs and open architectures provide.”

“This demonstration from Intel, QCT, and Radisys is important for accelerating broader adoption of 5G,” said Cristina Rodriguez, Intel VP and GM of Data Center Group, Wireless Access Network Division. “By defining the FlexRAN reference architecture and collaborating with our Intel Network Builders, Intel is expanding its growing portfolio of technology and ecosystem to ensure interoperability, enhanced performance, and reduced overhead for service providers all over the globe.”

For more information visit https://go.qct.io/telco/.

About Quanta Cloud Technology (QCT)

Quanta Cloud Technology (QCT) is a global data center solution provider. We combine the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.

Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Danny Chang
Danny_Chang@quantatw.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye